<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article16</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/PLATO" style="display:block; margin-bottom:10px;">PLATO Original</a></li>
<h2><strong>PLATO</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes". The New England Journal of Medicine. 2009. 361:1045-1057. PubMed•Full text•PDF<br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcome<br/>
8.2 Secondary Outcomes<br/>
8.3 Subgroup Analysis<br/>
9 Criticisms<br/>
10 Funding<br/>
11 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
In patients admitted with an acute coronary syndrome, does ticagrelor reduce the risk of cardiovascular events compared to clopidogrel?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
In patients with an acute coronary syndrome, ticagrelor was superior to clopidogrel in reducing the risk of death from vascular causes, myocardial infarction, or stroke, without an increased risk of overall major bleeding but with an increase in non–procedure-related bleeding.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/><br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
As of 2009, guidelines had not been published that reflect the results of this trial.<br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Multicenter, randomized, double-blind, double-dummy trial<br/>
N=18,624<br/>
Ticagrelor (n=9,333)<br/>
Clopidogrel (n=9,291)<br/>
Mean follow-up: 12 months<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
Inclusion Criteria: Hospitalized patients within 24 hours of onset of acute coronary syndromes with or without ST-segment elevation<br/>
Exclusion Criteria: Contraindications to clopidogrel, fibrinolytic therapy within 24 hours before randomization, need for oral anticoagulation, increased risk of bradycardia, strong cytochrome P-450 3A inhibitor or inducer therapy<br/>
Baseline Characteristics: Well balanced across both groups<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
Ticagrelor – 180 mg loading dose, followed by 90 mg twice daily<br/>
Clopidogrel – 300-600 mg loading dose if not previously received, followed by 75 mg daily<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcome: Death from vascular causes, myocardial infarction, or stroke at 12 months<br/>
9.8% with ticagrelor vs. 11.7% with clopidogrel (hazard ratio, 0.84; 95% CI, 0.77 to 0.92; P&lt;0.001)<br/>
<br/>
Secondary Outcomes<br/>
Death from any cause: 4.5% with ticagrelor vs. 5.9% with clopidogrel (P&lt;0.001)<br/>
No significant difference in the rates of major bleeding between groups<br/>
<br/>
Subgroup Analysis<br/>
Benefit of ticagrelor appeared to be attenuated in patients under median weight, those not taking lipid-lowering drugs at randomization, and those enrolled in North America<br/>
<br/>
<h2><strong>Criticisms</strong></h2><br/>
Ticagrelor was associated with a higher rate of major bleeding not related to coronary-artery bypass grafting and more instances of fatal intracranial bleeding.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
Supported by AstraZeneca.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
Full text article available at NEJM.org
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
